Pratik S. Multani

Pratik is Chief Medical Officer of ORIC Pharmaceuticals, which is discovering and developing therapies to overcome resistance in cancer. Prior to joining ORIC in September 2018, Pratik was Chief Medical Officer at Ignyta until its acquisition by Roche in February 2018. While at Ignyta, he led clinical and nonclinical development, as well as regulatory strategy for Ignyta’s portfolio of precision medicines in oncology, including entrectinib, a novel CNS-penetrant TRK and ROS1 inhibitor. Pratik’s background encompasses broad scientific and management experience in clinical development with a deep understanding of oncology. He served as Chief Medical Officer at Fate Therapeutics, where he led the clinical development of novel stem cell therapies for the treatment of hematologic malignancies and other rare diseases, and was involved in leadership positions for the development of multiple innovative marketed cancer therapies, including Treanda (bendamustine), Zevalin (ibritumomab tiuxtetan), and Rituxan (rituximab). Prior to joining industry, Pratik held academic and clinical positions at Harvard Medical School and Massachusetts General Hospital, where he was a member of the bone marrow transplant unit. He completed an internship and residency training in internal medicine at Massachusetts General Hospital and his oncology fellowship at the Dana Farber-Partners combined program. Pratik holds a B.S. from Yale University, an M.D. from Harvard Medical School, and an M.S. in Epidemiology from the Harvard School of Public Health.